3,4-dichlorobenzenediazonium cation | 30930-66-6

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 3,4-dichlorobenzenediazonium cation
• 英文别名: 3,4-Dichlor-benzoldiazonium-ion；3,4-Dichlor-benzoldiazonium；3.4-Dichlor-benzoldiazonium；3,4-Dichlorobenzenediazonium
• CAS: 30930-66-6
• 化学式: C₆H₃Cl₂N₂
• 分子量: 174.009
• InChiKey: MCCSLNXGIUCKJJ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.1
• 重原子数：
  10
• 可旋转键数：
  0
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  28.2
• 氢给体数：
  0
• 氢受体数：
  1

安全信息

• 海关编码：
  2927000090

反应信息

• 作为反应物：
  描述：

  3,4-dichlorobenzenediazonium cation 在 tin(ll) chloride 作用下， 生成 (3,4-二氯苯基)肼
  参考文献：
  名称：

  The Preparation of Substituted Hydrazines. IV. Arylhydrazines via Conventional Methods¹

  摘要：

  DOI：

  10.1021/jo01110a004

文献信息

• Predominance of 2-arylhydrazones of 1,3-diphenylpropane-1,2,3-trione over its proton-transfer products
  作者：Ryszard Gawinecki、Erkki Kolehmainen、Henryk Janota、Reijo Kauppinen、Maija Nissinen、Borys O?mia?owski

  DOI：10.1002/poc.435

  日期：2001.11

  substituent effect is transmitted effectively only to the hydrazone nitrogen and hydrogen atoms. Ab initio calculations show that the ketohydrazone tautomer is really very much favoured over its proton-transfer products in chloroform solution. The same tautomer was also detected in the crystal state by X-ray crystallography. Copyright © 2001 John Wiley & Sons, Ltd.

  通过15 N NMR化学位移在氯仿溶液中检测到1,3-二苯基-1,2,3-三酮的2-苯hydr是主要的互变异构形式。苯hydr部分中的取代基不影响该互变异构偏好。取代基效应仅有效地传递至的氮和氢原子。从头算计算表明，酮hydr互变异构体确实比氯仿溶液中的质子转移产物更受青睐。还通过X射线晶体学在晶体状态下检测到相同的互变异构体。版权所有©2001 John Wiley＆Sons，Ltd.
• [EN] PYRIDONE AND PYRIDAZONE ANALOGUES AS GPR119 MODULATORS<br/>[FR] ANALOGUES DE PYRIDONE ET DE PYRIDAZONE COMME MODULATEURS DE GPR119
  申请人：BRISTOL MYERS SQUIBB CO

  公开号：WO2010009183A1

  公开（公告）日：2010-01-21

  Novel compounds of structure Formula (I) or an enantiomer, a diastereomer, or a pharmaceutically acceptable salt thereof, wherein Z, R1, R2, R21, T1, T2, T3 and T4 are defined herein, are provided which are GPR119 G protein-coupled receptor modulators. GPR119 G protein-coupled receptor modulators are useful in treating, preventing, or slowing the progression of diseases requiring GPR119 G protein-coupled receptor modulator therapy. Thus, the disclosure also concerns compositions comprising these novel compounds and methods of treating diseases or conditions related to the activity of the GPR119 G protein-coupled receptor by using any of these novel compounds or a composition comprising any of such novel compounds.

  提供结构式（I）或其对映体、顺反异构体或药用可接受盐的新化合物，其中Z、R1、R2、R21、T1、T2、T3和T4在此定义，这些化合物是GPR119 G蛋白偶联受体调节剂。 GPR119 G蛋白偶联受体调节剂在治疗、预防或减缓需要GPR119 G蛋白偶联受体调节剂治疗的疾病方面是有用的。因此，该公开还涉及包含这些新化合物的组合物和使用任何这些新化合物或包含任何这种新化合物的组合物治疗与GPR119 G蛋白偶联受体活性相关的疾病或症状的方法。
• Visible Light-Driven, Gold(I)-Catalyzed Preparation of Symmetrical (Hetero)biaryls by Homocoupling of Arylazo Sulfones
  作者：Lorenzo Di Terlizzi、Simone Scaringi、Carlotta Raviola、Riccardo Pedrazzani、Marco Bandini、Maurizio Fagnoni、Stefano Protti

  DOI：10.1021/acs.joc.2c00225

  日期：2022.4.1

  The preparation of symmetrical (hetero)biaryls via arylazo sulfones has been successfully carried out upon visible light irradiation in the presence of PPh3AuCl as the catalyst. The present protocol led to the efficient synthesis of a wide range of target compounds in an organic-aqueous solvent under photocatalyst-free conditions.

  在PPh 3 AuCl作为催化剂的情况下，在可见光照射下成功地通过芳基偶氮砜制备了对称（杂）联芳基化合物。本方案可以在无光催化剂的条件下在有机水溶剂中有效合成多种目标化合物。
• PYRIDONE AND PYRIDAZONE ANALOGUES AS GPR119 MODULATORS
  申请人：Wacker Dean A.

  公开号：US20110263548A1

  公开（公告）日：2011-10-27

  Novel compounds of structure Formula (I) or an enantiomer, a diastereomer, or a pharmaceutically acceptable salt thereof, wherein Z, R 1 , R 2 , R 21 , T 1 , T 2 , T 3 and T 4 are defined herein, are provided which are GPR119 G protein-coupled receptor modulators. GPR119 G protein-coupled receptor modulators are useful in treating, preventing, or slowing the progression of diseases requiring GPR119 G protein-coupled receptor modulator therapy. Thus, the disclosure also concerns compositions comprising these novel compounds and methods of treating diseases or conditions related to the activity of the GPR119 G protein-coupled receptor by using any of these novel compounds or a composition comprising any of such novel compounds.

  提供了结构式（I）或其对映异构体、非对映异构体或药学上可接受的盐的新化合物，其中Z、R1、R2、R21、T1、T2、T3和T4在此定义，这些化合物是GPR119 G蛋白偶联受体调节剂。 GPR119 G蛋白偶联受体调节剂在治疗、预防或减缓需要GPR119 G蛋白偶联受体调节剂治疗的疾病方面是有用的。因此，本公开还涉及包含这些新化合物的组合物以及使用任何这些新化合物或包含任何这些新化合物的组合物来治疗与GPR119 G蛋白偶联受体活性相关的疾病或病况的方法。
• Pyridone and pyridazone analogues as GPR119 modulators
  申请人：Wacker Dean A.

  公开号：US08372837B2

  公开（公告）日：2013-02-12

  Novel compounds of structure Formula (I) or an enantiomer, a diastereomer, or a pharmaceutically acceptable salt thereof, wherein Z, R1, R2, R21, T1, T2, T3 and T4 are defined herein, are provided which are GPR119 G protein-coupled receptor modulators. GPR119 G protein-coupled receptor modulators are useful in treating, preventing, or slowing the progression of diseases requiring GPR119 G protein-coupled receptor modulator therapy. Thus, the disclosure also concerns compositions comprising these novel compounds and methods of treating diseases or conditions related to the activity of the GPR119 G protein-coupled receptor by using any of these novel compounds or a composition comprising any of such novel compounds.

  本文提供结构式（I）或其对映体、非对映异构体或药学上可接受的盐的新化合物，其中Z、R1、R2、R21、T1、T2、T3和T4在此被定义，这些化合物是GPR119 G蛋白偶联受体调节剂。 GPR119 G蛋白偶联受体调节剂在治疗、预防或减缓需要GPR119 G蛋白偶联受体调节剂治疗的疾病方面是有用的。因此，本文还涉及包含这些新化合物的组合物以及使用任何这些新化合物或包含任何这些新化合物的组合物治疗与GPR119 G蛋白偶联受体活性相关的疾病或状况的方法。